JULIE ERPS: Open Payments
NPI 1992849236 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,902 in 82 payments from 14 companies in 2025. Trend: 2023 $940 · 2024 $1,313 · 2025 $1,902
Food & beverage: $1,902
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $549 |
| Madrigal Pharmaceuticals | 11 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $271 |
| Novo Nordisk Inc | 3 | $150 |
| Gilead Sciences, Inc. | 6 | $142 |
| VIVUS LLC | 5 | $117 |
| PFIZER INC. | 5 | $110 |
| Aimmune Therapeutics, Inc. | 4 | $86 |
| Janssen Biotech, Inc. | 2 | $50 |
| Celltrion USA Inc. | 2 | $45 |
Products named: REZDIFFRA, ENTYVIO, RINVOQ, SKYRIZI, Wegovy, PANCREAZE, CREON, ZENPEP.
Industry payments across TX — which companies pay providers there.
